Samuel Washington III, MD, MAS

Samuel Washington III, MD, MAS

Goldberg-Benioff Endowed Professorship in Cancer Biology, UCSF

Assistant Professor of Urology; Epidemiology & Biostatistics; Community Engagement Liaison, Prostate Cancer Program, Helen Diller Family Comprehensive Cancer Center; Associate Chair of Diversity, Equity, and Inclusion; Department of Urology, UCSF

Cancer Center Program Membership

Prostate Cancer

Phone: (415) 476-4616 (appts)

Box 1695, UCSF
San Francisco, CA 94143

Physician Biography

UCSF Profiles

Research Summary

As a urologic oncologist, my practice is primarily focused on the surgical management of individuals with genitourinary cancers. My research has been focused primarily on clinical research related to outcomes, with an emphasis on access to care and disparities in receipt of healthcare for individuals with prostate and bladder cancer.

Research Funding

  • December 2, 2021 - November 30, 2024 - An Atlas of Human Prostate AcrossAncestries to develop a comprehensive atlas of the human pros-tate at single-cell resolution with a community engagement plan to maximize impact for the public and clinical and scientific communities , Co-Principal Investigator . Sponsor: Chan Zuckerberg Initiative DAF, Sponsor Award ID: P0559192
  • December 1, 2021 - November 30, 2022 - Drivers of racial disparities in management of advanced prostate cancer: examining local and geo-graphic variations in evaluation and treatment. , Principal Investigator . Sponsor: ConcertAI, Sponsor Award ID:
  • October 1, 2019 - October 1, 2020 - Impact of socioeconomic status on overutilization of healthcare expenditure in patients with bladder cancer , Co-Investigator . Sponsor: OptumLabs, Sponsor Award ID: 20183
  • July 1, 2018 - June 30, 2019 - The Differential Impact of Race on Oncologic Outcomes in Elderly Patients with Bladder Cancer: A Population-based Study , Co-Principal Investigator . Sponsor: NIA RCMAR/UCSF Center for Aging in Diverse Communities Scholars Program, Sponsor Award ID: 132016C

Education

  • University of California, Davis, BS, 2007, Genetics
  • University of California, San Francisco, MD, 2012
  • University of California, San Francisco, MOTH, 2019, Masters of Advanced Study in Clinical Research
  • University of California, San Francisco, Resident, 2018, Urology
  • University of California, San Francisco, Postdoctoral Fellow, 2020, Urologic Oncology

Honors & Awards

  • 2021 - 2022
    Engaging Research to Achieve Cancer Care Equity (ERACE) Research Award, ConcertAI
  • 2021
    Goldberg-Benioff Endowed Professorship in Cancer Biology, University of California, San Francisco
  • 2021
    Grunfeld Scholar, San Francisco VA Healthcare System Research Development Initiative
  • 2021
    John A. Watson Faculty Scholar, Dean's Diversity Fund, University of California, San Francisco
  • 2019 - 2020
    OptumLabs Health Data for Action: Leveraging Health Data for Actionable Insights Data Access Award, OptumLabs
  • 2018 - 2019
    UCSF CADC Scholar, UCSF Center for Aging in Diverse Communities
  • 2010 - 2011
    Pathways to Careers in Clinical and Translational Research Yearlong Fellowship, University of California, San Francisco
  • 2009 - 2009
    Dean's Summer Research Fellowship, University of California, San Francisco

Selected Publications

  1. Cabral J, Holt SK, Washington SL, Dwyer E, Lee JR, Wolff EM, Gore JL, Nyame YA. Inequities in Definitive Treatment for Localized Prostate Cancer Among Those With Clinically Significant Mental Health Disorders. Urol Pract. 2023 Sep 26; 101097UPJ0000000000000457.  View on PubMed
  2. Washington SL, Lonergan PE, Cowan JE, Zhao S, Broering JM, Palmer NR, Hicks C, Cooperberg MR, Carroll PR. Ten-year work burden after prostate cancer treatment. Cancer Med. 2023 Sep 19.  View on PubMed
  3. Javier-DesLoges J, Dall'Era MA, Brisbane W, Chamie K, Washington SL, Chandrasekar T, Marks LS, Nguyen H, Daneshvar M, Gin G, Kane CJ, Bagrodia A, Cooperberg MR. The state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement. Prostate Cancer Prostatic Dis. 2023 Aug 08.  View on PubMed
  4. Djaïleb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Rajagopal A, Grogan TR, Nguyen K, Benz MR, Hotta M, Barbato F, Ceci F, Schwarzenböck SM, Unterrainer M, Zacho HD, Juarez R, Cooperberg M, Carroll P, Washington S, Reiter RE, Eiber M, Herrmann K, Fendler WP, Czernin J, Hope TA, Calais J. Presurgical 68Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial. Eur Urol. 2023 Jul 21.  View on PubMed
  5. Chappidi MR, Sjöström M, Greenland NY, Cowan JE, Baskin AS, Shee K, Simko JP, Chan E, Stohr BA, Washington SL, Nguyen HG, Quigley DA, Davicioni E, Feng FY, Carroll PR, Cooperberg MR. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes. Eur Urol Oncol. 2023 Jul 18.  View on PubMed
  6. Han JH, Lee S, Lee B, Baek OK, Washington SL, Herlemann A, Lonergan PE, Carroll PR, Jeong CW, Cooperberg MR. Explainable ML models for a deeper insight on treatment decision for localized prostate cancer. Sci Rep. 2023 07 17; 13(1):11532.  View on PubMed
  7. Baskin A, Cowan JE, Braun A, Lonergan PE, Mohamad O, Washington SL, Zhao S, Broering JM, Cooperberg MR, Breyer BN, Carroll PR. Long-term complications and health-related quality of life outcomes after radical prostatectomy with or without subsequent radiation treatment for prostate cancer. Urol Oncol. 2023 Jul 03.  View on PubMed
  8. Loeb S, Ravenell JE, Gomez SL, Borno HT, Siu K, Sanchez Nolasco T, Byrne N, Wilson G, Griffith DM, Crocker R, Sherman R, Washington SL, Langford AT. The Effect of Racial Concordance on Patient Trust in Online Videos About Prostate Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2023 07 03; 6(7):e2324395.  View on PubMed
  9. Chappidi MR, Escobar D, Meng MV, Washington SL, Porten SP. Readmissions trends following radical cystectomy for bladder cancer unchanged in the era of enhanced recovery after surgery (ERAS) protocols. Urol Oncol. 2023 08; 41(8):355.e19-355.e28.  View on PubMed
  10. Lonergan PE, Baskin A, Greenberg SA, Mohamad O, Washington SL, Zhao S, Cowan JE, Broering JM, Nguyen HG, Cooperberg MR, Breyer BN, Carroll PR. The Long-term Incidence and Quality of Life Outcomes Associated With Treatment-Related Toxicities of External Beam Radiotherapy for Prostate Cancer. Urology. 2023 Aug; 178:114-119.  View on PubMed
  11. Chang K, Greenberg SA, Cowan JE, Parker R, Shee K, Washington SL, Nguyen HG, Shinohara K, Carroll PR, Cooperberg MR. Stability of Prognostic Estimation Using the CAPRA Score Incorporating Imaging-based vs Physical Exam-based Staging. J Urol. 2023 Aug; 210(2):281-289.  View on PubMed
  12. Parker R, Bell A, Chang K, Greenberg S, Washington SL, Cowan JE, Carroll PR, Cooperberg MR. PSA density does not improve predictive accuracy of the UCSF-CAPRA score. Prostate. 2023 07; 83(10):922-928.  View on PubMed
  13. Chu CE, Leapman MS, Zhao S, Cowan JE, Washington SL, Cooperberg MR. Prostate cancer disparities among American Indians and Alaskan Natives in the United States. J Natl Cancer Inst. 2023 04 11; 115(4):413-420.  View on PubMed
  14. Han JH, Herlemann A, Washington SL, Lonergan PE, Carroll PR, Cooperberg MR, Jeong CW. Observation, Radiotherapy, or Radical Prostatectomy for Localized Prostate Cancer: Survival Analysis in the United States. World J Mens Health. 2023 Mar 15.  View on PubMed
  15. Shee K, Cowan JE, Balakrishnan A, Escobar D, Chang K, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. Limited Relevance of the Very Low Risk Prostate Cancer Classification in the Modern Era: Results from a Large Institutional Active Surveillance Cohort. Eur Urol. 2023 07; 84(1):9-12.  View on PubMed
  16. Sabbagh A, Washington SL, Tilki D, Hong JC, Feng J, Valdes G, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Cowan JE, Cooperberg M, Feng FY, Roach M, Trock BJ, Partin AW, D'Amico AV, Carroll PR, Mohamad O. Development and External Validation of a Machine Learning Model for Prediction of Lymph Node Metastasis in Patients with Prostate Cancer. Eur Urol Oncol. 2023 Mar 01.  View on PubMed
  17. Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall'Era M, Davis JW, Drake BF, Epstein JI, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, Kauffman E, Kaye D, Kibel AS, LaGrange CA, Maroni P, Ponsky L, Reys B, Salami SS, Sanchez A, Seibert TM, Shaneyfelt TM, Smaldone MC, Sonn G, Tyson MD, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi RA, Freedman-Cass DA. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. J Natl Compr Canc Netw. 2023 03; 21(3):236-246.  View on PubMed
  18. Caram MEV, Kumbier K, Burns J, Sparks JB, Tsao PA, Stensland KD, Washington SL, Hollenbeck BK, Shahinian V, Skolarus TA. Differential adoption of castration-resistant prostate cancer treatment across facilities in a national healthcare system. Cancer Med. 2023 03; 12(6):6945-6955.  View on PubMed
  19. Szymaniak JA, Washington SL, Cowan JE, Cooperberg MR, Lonergan PE, Nguyen HG, Meng MV, Carroll PR. The natural history of a delayed detectable PSA after radical prostatectomy. Prostate Cancer Prostatic Dis. 2023 Feb 10.  View on PubMed
  20. Pittman A, Moses KA, Washington SL. Urologists in Advocacy: The Key to Addressing Disparities in Prostate Cancer. J Urol. 2022 Nov 17; 101097JU0000000000003000.  View on PubMed

Go to UCSF Profiles, powered by CTSI